Egypt is entering a new phase in the evolution of its pharmaceutical industry. Having built one of the largest pharmaceutical manufacturing bases in the Middle East and Africa, the country is now seeking to expand into biotechnology, producing vaccines, biologic medicines, biosimilars and other advanced therapies that command significantly higher value than conventional pharmaceuticals. As countries across Africa and the Middle East strengthen healthcare resilience following the COVID-19 pandemic, biotechnology is increasingly viewed as both a public health priority and a strategic industrial opportunity.
A Strong Pharmaceutical Foundation
Egypt enters the biotechnology race from a position of considerable strength. According to the Egyptian Drug Authority (EDA), the pharmaceutical market reached EGP 422 billion (approximately US$8.5 billion) in 2025, growing by 37% year-on-year. Domestic manufacturers now supply around 91% of medicines consumed locally, while national localization efforts focus on producing the 50 most imported active pharmaceutical ingredients (APIs) and expanding high-value pharmaceutical manufacturing.
The World Health Organization (WHO) identifies Egypt as one of the largest pharmaceutical markets in the Middle East and Africa, supported by 177 operational manufacturing facilities. This industrial base provides a strong platform for expanding into biotechnology.
Unlike conventional medicines, biologics—including monoclonal antibodies, recombinant proteins, biosimilars and advanced vaccines—are produced using living cells and complex biological processes. Their manufacture requires sophisticated facilities, advanced quality systems, highly skilled scientists and robust regulatory oversight, making biotechnology one of the pharmaceutical industry’s highest-value segments.
Building Manufacturing Capabilities
Egypt has already demonstrated its biotechnology potential. During the COVID-19 pandemic, VACSERA produced more than 45 million vaccine doses, showcasing the country’s ability to manufacture complex biological products through technology transfer and advanced production systems. The experience strengthened capabilities in sterile manufacturing, quality assurance, cold-chain logistics and regulatory compliance that underpin modern biomanufacturing.
Regulatory progress has become another competitive advantage. The EDA has achieved WHO Maturity Level 3 (ML3) for medicines and vaccines, confirming that Egypt’s regulatory framework meets internationally recognized standards. In May 2026, WHO also designated the EDA’s Continuous Professional Development Center as the Regional Training Centre for Biomanufacturing for the Eastern Mediterranean, supporting regional expertise in vaccines, biologics, regulatory science and technology transfer.
The designation highlights the importance of skilled human capital. Biotechnology depends on expertise in molecular biology, biochemical engineering, pharmaceutical quality systems and regulatory science as much as manufacturing infrastructure.
A Regional Biotechnology Ambition
Egypt’s ambitions extend beyond domestic healthcare. Pharmaceutical exports reached approximately US$1.3 billion in 2025, with the EDA targeting US$3 billion by 2030, including US$1.34 billion in exports to African markets. The strategy combines export growth with regional manufacturing partnerships and technology transfer.
Africa’s rapidly expanding healthcare market presents significant opportunities as governments seek greater pharmaceutical self-sufficiency. Egypt’s large manufacturing base, improving regulatory framework and strategic location provide a competitive advantage in serving both African and Middle Eastern markets.
Competition is intensifying, with Saudi Arabia, the United Arab Emirates and Morocco also investing heavily in biotechnology and life sciences. Egypt’s advantage lies in combining established pharmaceutical manufacturing capacity with internationally recognized regulation and access to two of the world’s fastest-growing healthcare markets.
The Next Stage of Growth
Moving from pharmaceutical manufacturing to biotechnology leadership will require continued investment in research and development, advanced facilities, specialized talent and international partnerships. Success will depend not only on producing larger volumes of medicines but also on developing the scientific and technological capabilities needed for increasingly sophisticated biological products.
With its established pharmaceutical industry, expanding regulatory capacity and growing expertise in biomanufacturing, Egypt is well positioned to become a leading biotechnology hub in the Middle East and Africa, strengthening regional healthcare security while creating new opportunities for industrial growth, exports and scientific innovation.
Related news:The Egypt Opportunity: Why Health, Food and Agriculture Could Turn a Massive Market into a Regional Production Hub
Egypt to Lead Middle East with First Biopharmaceutical Plant Launch in 2025
Health 2035: Can Egypt Become the Middle East’s Next Healthcare and Food Production Hub?
Read also:
Saudi-US Partnership Targets $500m to Advance Kingdom’s Biotechnology Ambitions
